{
  "id": "everyday#referral_d0b70409",
  "title_en": "General — Referral",
  "title_vi": "General — Chuyển tuyến",
  "text_en": "and substance use disorders Research gaps newer antipsychotics may have higher costs than y Most of the evidence is from HICs. Further research is older first-generation antipsychotics. needed in LMICs. y Interruptions in medicine availability (common y There was no evidence for maintenance therapy in LMICs and in supply chain interruption such for more than two years and evidence was scarce as during emergencies) may interfere with between one- and two-year follow-up. More studies continuation of treatment. Reliability of supply are required on longer term maintenance. should inform choice of medicine. y More studies applying gradual tapering of the y For the treatment of psychotic disorders, the WHO antipsychotic in the placebo group are needed. EML (13) includes: – fluphenazine (therapeutic alternatives: Implementation considerations haloperidol decanonate, zuclopenthixol y As individuals with a first psychotic episode usually decanonate); respond well to antipsychotics, drug choice should – haloperidol (therapeutic alternative: be mainly based on side-effect profiles. chlorpromazine); y People living with schizophrenia should – haloperidol injection; be involved in drug choice in a supported – olanzapine; decision-making process. – paliperidone (therapeutic alternative: y Treatment with antipsychotic medicines should risperidone injection); be combined with psychosocial interventions (see – risperidone (therapeutic alternatives: aripiprazole, other PICO questions in this module). olanzapine, paliperidone, quetiapine); y Acquisition costs can differ substantially. Also, – complementary list: clozapine. throughout the world, second-generation and other PSY3. In adults with bipolar disorder in remission, how long should antipsychotic medicine or mood stabilizers be continued after remission in order to allow for the best outcomes? Recommendation (update): Maintenance therapy with mood stabilizers or antipsychotic medicines should be considered for at least six months for adults with bipolar disorder in remission, carefully balancing effectiveness, side-effects and individual preference. Strength of recommendation: Conditional Certainty of evidence: Low Justification Thoma et al., 2018 (596 RCTs on second-generation y Evidence was extracted from three systematic antipsychotic medicines and short-term mortality in reviews: Kishi et al., 2021 (22 RCTs comparing individuals with severe mental illness) (193). between antipsychotic/mood stabilizer y The anticipated desirable effects for maintenance discontinuation and maintenance groups in therapy are moderate to large for recurrence rate individuals with bipolar disorder) (195); Kishi et of any mood episode/depressive episode/manic, al., 2021 (41 RCTs on antipsychotics and/or mood hypomanic or mixed episode at different time stabilizers for individuals with bipolar disorder points. Most data were available for a follow-up of up in the maintenance phase) (196); and Schneider- to six months. 90",
  "gloss_vi": "And substance use disorders research gaps newer antipsychotics may have higher costs than y most of the evidence is from hics. further research is older first-generation antipsychotics.",
  "source": "Everyday Essentials",
  "url": "",
  "lang": "en",
  "axes": {
    "type": [
      "clinical"
    ],
    "condition": [
      "General"
    ],
    "clinical_section": [
      "referral",
      "psychoeducation"
    ],
    "life_topics": [],
    "advice_section": [],
    "audience": [],
    "risk_band": "low"
  },
  "index_text": "General — Referral General — Chuyển tuyến and substance use disorders Research gaps newer antipsychotics may have higher costs than y Most of the evidence is from HICs. Further research is older first-generation antipsychotics. needed in LMICs. y Interruptions in medicine availability (common y There was no evidence for maintenance therapy in LMICs and in supply chain interruption such for more than two years and evidence was scarce as during emergencies) may interfere with between one- and two-year follow-up. More studies continuation of treatment. Reliability of supply are required on longer term maintenance. should inform choice of medicine. y More studies applying gradual tapering of the y For the treatment of psychotic disorders, the WHO antipsychotic in the placebo group are needed. EML (13) includes: – fluphenazine (therapeutic alternatives: Implementation considerations haloperidol decanonate, zuclopenthixol y As individuals with a first psychotic episode usually decanonate); respond well to antipsychotics, drug choice should – haloperidol (therapeutic alternative: be mainly based on side-effect profiles. chlorpromazine); y People living with schizophrenia should – haloperidol injection; be involved in drug choice in a supported – olanzapine; decision-making process. – paliperidone (therapeutic alternative: y Treatment with antipsychotic medicines should risperidone injection); be combined with psychosocial interventions (see – risperidone (therapeutic alternatives: aripiprazole, other PICO questions in this module). olanzapine, paliperidone, quetiapine); y Acquisition costs can differ substantially. Also, – complementary list: clozapine. throughout the world, second-generation and other PSY3. In adults with bipolar disorder in remission, how long should antipsychotic medicine or mood stabilizers be continued after remission in order to allow for the best outcomes? Recommendation (update): Maintenance therapy with mood stabilizers or antipsychotic medicines should be considered for at least six months for adults with bipolar disorder in remission, carefully balancing effectiveness, side-effects and individual preference. Strength of recommendation: Conditional Certainty of evidence: Low Justification Thoma et al., 2018 (596 RCTs on second-generation y Evidence was extracted from three systematic antipsychotic medicines and short-term mortality in reviews: Kishi et al., 2021 (22 RCTs comparing individuals with severe mental illness) (193). between antipsychotic/mood stabilizer y The anticipated desirable effects for maintenance discontinuation and maintenance groups in therapy are moderate to large for recurrence rate individuals with bipolar disorder) (195); Kishi et of any mood episode/depressive episode/manic, al., 2021 (41 RCTs on antipsychotics and/or mood hypomanic or mixed episode at different time stabilizers for individuals with bipolar disorder points. Most data were available for a follow-up of up in the maintenance phase) (196); and Schneider- to six months. 90 And substance use disorders research gaps newer antipsychotics may have higher costs than y most of the evidence is from hics. further research is older first-generation antipsychotics."
}